Regencell Bioscience Holdings RGC
NASDAQ RGC
$10.65 -0.15 (-1.39%)
As of: Oct 22, 2026 · 10:03 AM EDT

Regencell Bioscience Holdings (RGC) Short term Debt (2020 - 2021)

Updated

Regencell Bioscience Holdings (RGC) recorded Short term Debt of $431,969 in the quarter ended Jun 30, 2021, down 100.0% from $3.07 trillion a year earlier.

Analysis

Regencell Bioscience Holdings (RGC) Short term Debt (2020 - 2021) Analysis & Trends

  • Across earlier years, Short term Debt came in at $3.07 trillion in the year ended Jun 30, 2020.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,163.48 Bn 1,132.06 Bn 19.71 Bn
2 Johnson & Johnson 631.16 Bn 549.69 Bn 17.26 Bn
3 AbbVie 502.63 Bn 475.74 Bn 12.70 Bn
4 Merck 378.53 Bn 332.91 Bn 12.21 Bn
5 Novartis Ag 302.83 Bn 266.82 Bn 11.24 Bn
6 Astrazeneca 265.92 Bn 239.60 Bn 12.86 Bn
7 Amgen 240.87 Bn 196.27 Bn 7.24 Bn
8 Gilead Sciences 194.04 Bn 168.24 Bn 6.22 Bn
9 Pfizer 172.14 Bn 118.78 Bn 10.94 Bn
10 Regencell Bioscience Holdings 5.27 Bn 5.24 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 431,969.00
Jun 30, 2020 3.07 Mn
API Access

Regencell Bioscience Holdings Short term Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=short-term-debt&ticker=RGC&period=max&api_key=YOUR_API_KEY